Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025

Core Insights - Merck plans to present new research from its cardio-pulmonary portfolio and pipeline at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, Louisiana, from November 7–10 [1] - The data presented at AHA will emphasize Merck's commitment to advancing research in hypercholesterolemia and pulmonary arterial hypertension (PAH) [1] Company Focus - The company is dedicated to addressing the global burden of diseases related to hypercholesterolemia and PAH through innovative research [1]